Details for New Drug Application (NDA): 060522
✉ Email this page to a colleague
NDA 060522 describes HUMATIN, which is a drug marketed by King Pfizer, Parkedale, and Parke Davis, and is included in three NDAs. Additional details are available on the HUMATIN profile page.
The generic ingredient in HUMATIN is paromomycin sulfate. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the paromomycin sulfate profile page.
The generic ingredient in HUMATIN is paromomycin sulfate. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the paromomycin sulfate profile page.
Summary for 060522
| Tradename: | HUMATIN |
| Applicant: | Parke Davis |
| Ingredient: | paromomycin sulfate |
| Patents: | 0 |
Medical Subject Heading (MeSH) Categories for 060522
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | SYRUP;ORAL | Strength | EQ 125MG BASE/5ML | ||||
| Approval Date: | Approved Prior to Jan 1, 1982 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
